*****************ELTP****************** . Near term Goals : ELI 200 submission in 2015 & approval in 2016 Continuing manufacturing facility´s expansion, equipment upgrade and staffing - Loxapine & Dantrolene launch - Filling two more opioid products in 2016 - ELI 200 product launch with marketing partner Revenue growth from niche generics and first ADF product Profitability Base generic business profitable in 2016 R&D costs supported with ELI 200 in 2017 Elite Pharmaceuticals, Inc. Reports Strong Growth for Second Quarter of Fiscal Year 2016 http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=79776&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0